In Silico Modeling Unveils a New Era in Rare Disease Drug Development
The Premier Consulting Blog
JUNE 18, 2023
More recently, some key events that have enabled acceptance of in silico trials for evaluating treatments for rare diseases include: In 2016, the FDA formed the Modeling and Simulation Working Group to support the implementation of CM&S in the regulatory review process. BMC Bioinformatics 2020, 21(Suppl 17):527 [link]
Let's personalize your content